Susan Kozauer
Intra-Cellular Therapies, Inc. · Intra-Cellular Therapies, Inc. (ITI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Susan Kozauer as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 02:20 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04285515 · Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive DisorderIntra-Cellular Therapies, Inc. · completed · Bipolar Depression, Major Depressive Disorder · study director
- Ph3NCT03249376 · Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted GloballyIntra-Cellular Therapies, Inc. · completed · Bipolar Depression · study director
- Ph3NCT02817906 · ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's DiseaseIntra-Cellular Therapies, Inc. · terminated · Agitation in Dementia, Including Alzheimer's Disease · study director
- Ph3NCT02600507 · Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar DepressionIntra-Cellular Therapies, Inc. · completed · Bipolar Depression · study director
- Ph3NCT02600494 · Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar DepressionIntra-Cellular Therapies, Inc. · completed · Bipolar Depression · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 02:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 02:20 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial.Am J Psychiatry · 202180 citationsRCR 6.7
- Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial.Bipolar Disord · 202323 citationsRCR 3.8
- The efficacy of lumateperone on symptoms of depression in bipolar I and bipolar II disorder: Secondary and post hoc analyses.Eur Neuropsychopharmacol · 202319 citationsRCR 3.2
- Lumateperone for the Treatment of Major Depressive Disorder With Mixed Features or Bipolar Depression With Mixed Features: A Randomized Placebo-Controlled Trial.J Clin Psychopharmacol · 202514 citationsRCR 7.2
- The Efficacy of Lumateperone in Patients With Bipolar Depression With Mixed Features.J Clin Psychiatry · 202313 citationsRCR 2.3
- Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial.J Clin Psychiatry · 202510 citationsRCR 4.7
- Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial.Am J Psychiatry · 20259 citationsRCR 4.1